辉瑞(PFE)PD-L1 ADC在国内启动Ⅰ期临床

金吾财讯
13 May

金吾财讯 | 5月12日,药物临床试验登记与信息公示平台显示,辉瑞(PFE)在国内启动了一项PF-08046054针对实体瘤患者的Ⅰ期临床。PF-08046054(SGN-PDL1V)是辉瑞收购Seagen获得的一款靶向PD-L1的ADC。这项Ⅰ期临床旨在评估PF-08046054作为单药治疗晚期实体恶性肿瘤受试者。Insight数据库显示,全球目前共有2款靶向PD-L1的ADC进入临床阶段。除了辉瑞的PF-08046054,另外一款为宜联生物/复宏汉霖的HLX43,目前正在开展Ⅱ期临床阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10